Document Detail

Second autologous or allogeneic transplantation after the failure of first autograft in patients with multiple myeloma.
MedLine Citation:
PMID:  16456814     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: Most patients undergoing high-dose therapy and autologous transplant for multiple myeloma eventually develop a disease recurrence. However, to the authors' knowledge, the optimal salvage treatment for these patients is not well defined. Both autologous and allogeneic hematopoietic stem cell transplantations have been used for salvage therapy. The outcomes of salvage autologous or allogeneic transplants were analyzed retrospectively in patients relapsing after an autograft. METHODS: Fourteen patients (median age, 52 yrs) received a second autograft for salvage, whereas 26 patients (median age, 51 yrs) underwent a reduced-intensity allogeneic transplantation (related in 18 patients and unrelated in 8 patients). The median interval between the first and the second transplant was 25 months in the autologous group and 17 months in the allogeneic group. The two groups were evenly matched with regard to other disease characteristics. RESULTS: After a median follow-up of 18 months for the autologous group and 30 months for the allogeneic group, the median progression-free survival (PFS) and overall survival (OS) in the 2 groups were 6.8 months versus 7.3 months and 29 months versus 13 months, respectively. Acute and chronic graft versus host disease (15%) was the most common cause of non-recurrence mortality in the allogeneic group and infections (14%) in the autologous group. On univariate analysis, an interval of > 1 year between the first and the salvage transplant predicted a better OS in the allogeneic group. CONCLUSIONS: Both autografting and allografting are feasible as salvage therapy for myeloma patients who develop disease recurrence after the first autograft, although disease progression remains the major cause of failure. Better approaches are needed for salvage therapy in patients developing disease recurrence after an autograft.
Muzaffar H Qazilbash; Rima Saliba; Marcos De Lima; Chitra Hosing; Daniel Couriel; Ana Aleman; Linda Roden; Richard Champlin; Sergio A Giralt
Related Documents :
9535604 - Treatment for advanced testicular cancer with high-dose chemotherapy and autologous blo...
15570254 - Use of a t cell-specific monoclonal antibody, t10b9, in a novel allogeneic stem cell tr...
20528244 - Long-term results of high-dose chemotherapy with autologous bone marrow or peripheral s...
19956494 - High-dose chemotherapy of cyclophosphamide, thiotepa and carboplatin (ctcb) followed by...
22916994 - Radiotherapy in the management of localized primary cutaneous b-cell lymphoma.
6421344 - Comparison of two long-term chemotherapy regimens, with or without agents to modify ske...
Publication Detail:
Type:  Clinical Trial; Journal Article    
Journal Detail:
Title:  Cancer     Volume:  106     ISSN:  0008-543X     ISO Abbreviation:  Cancer     Publication Date:  2006 Mar 
Date Detail:
Created Date:  2006-02-23     Completed Date:  2006-03-28     Revised Date:  2006-04-24    
Medline Journal Info:
Nlm Unique ID:  0374236     Medline TA:  Cancer     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1084-9     Citation Subset:  AIM; IM    
Department of Blood and Marrow Transplantation, University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Hematopoietic Stem Cell Transplantation*
Middle Aged
Multiple Myeloma / therapy*
Salvage Therapy
Survival Analysis
Transplantation, Autologous
Transplantation, Homologous
Treatment Outcome

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Expression of FasL in squamous cell carcinomas of the cervix and cervical intraepithelial neoplasia ...
Next Document:  Nuclear expression of the antiapoptotic protein survivin in malignant melanoma.